Identification of a Proliferation Gene Cluster Associated with HPV E6/E7
  Expression Level and Viral DNA Load in Invasive Cervical Carcinoma by Rosty, Christophe et al.
 1
Identification of a Proliferation Gene Cluster Associated with HPV E6/E7 Expression 
Level and Viral DNA Load in Invasive Cervical Carcinoma 
 
Christophe Rosty1,2, Michal Sheffer3*, Dafna Tsafrir3*, Nicolas Stransky2, Ilan Tsafrir3, 
Martine Peter1, Patricia de Crémoux1, Anne de La Rochefordière4, Rémy Salmon5, Thierry 
Dorval6, Jean Paul Thiery7, Jérôme Couturier1, François Radvanyi2, Eytan Domany3, Xavier 
Sastre-Garau1 
*These authors have contributed equally to the analysis of the data 
 
Département de Biologie des Tumeurs1, Oncologie Moléculaire UMR144 CNRS2, 
Département de Radiothérapie4, Département de Chirurgie5, Département d’Oncologie 
Médicale6, Département de Transfert7, Institut Curie, 26 rue d’Ulm, 75248 Paris Cedex 05, 
France 
Department of Physics of Complex Systems3, Weizmann Institute of Science, Rehovot, Israel 
 
Running title: Gene expression in invasive cervical carcinoma 
Key words: cervical cancer, gene expression, HPV, prognosis, bioinformatics 
Proofs addressed to: Dr. Xavier Sastre-Garau 
   Departement de Pathologie 
Institut Curie, Section Médicale 
26 rue d’Ulm 
75248 Paris Cedex 05, France 
Email : xavier.sastre@curie.net 
Phone : +33 1 44 32 42 50 
Fax : +33 1 44 32 40 72 
 2
ABSTRACT 
Specific HPV DNA sequences are associated with more than 90% of invasive carcinomas of 
the uterine cervix. Viral E6 and E7 oncogenes are key mediators in cell transformation by 
disrupting TP53 and RB pathways. To investigate molecular mechanisms involved in the 
progression of invasive cervical carcinoma, we performed a gene expression study on cases 
selected according to viral and clinical parameters. Using Coupled Two-Way Clustering and 
Sorting Points Into Neighbourhoods methods, we identified a ‘Cervical Cancer Proliferation 
Cluster’ composed of 163 highly correlated transcripts, many of which corresponded to E2F 
pathway genes controlling cell proliferation, whereas no TP53 primary target was present in 
this cluster. The average expression level of the genes of this cluster was higher in tumours 
with an early relapse than in tumours with a favourable course (P=0.026). Moreover, we 
found that E6/E7 mRNA expression level was positively correlated with the expression level 
of the cluster genes and with viral DNA load. These findings suggest that HPV E6/E7 
expression level plays a key role in the progression of invasive carcinoma of the uterine 
cervix via the deregulation of cellular genes controlling tumour cell proliferation. HPV 
expression level may thus provide a biological marker useful for prognosis assessment and 
specific therapy of the disease. 
 3
INTRODUCTION 
DNA sequences of specific HPV types are detected in the vast majority of invasive cervical 
carcinoma (Bosch et al., 1995), a worldwide and frequent disease (Ferlay et al., 2001). HPV 
16 and 18, corresponding to highly oncogenic genotypes, are detected in 59% and 15% of the 
cases, respectively (Clifford et al., 2003). E6 and E7 viral oncoproteins are major contributors 
to neoplastic progression by interfering with cell cycle G1-S checkpoint (for review, (zur 
Hausen, 2002)). Among a variety of cellular targets, E6 binds and degrades TP53 protein by 
forming a complex with the ligase E6AP, leading to genetic instability. E7 abrogates pRB 
protein function through its ubiquitination-mediated degradation, which leads to activation of 
E2F regulated genes and deregulates the progression through the G1 phase of the cell cycle. 
Integration of viral sequences into the host genome interrupts E2 open reading frame, leading 
to the constitutive expression of E6/E7 in the transformed cells (Romanczuk & Howley, 
1992). 
Most cases of early stage invasive cervical carcinoma can be cured by a combination of 
surgery, radiotherapy and chemotherapy (Gerbaulet et al., 1992; Morris et al., 1999). 
However, some tumours relapse at short term and are lethal in most of the cases, despite 
chemotherapy (Omura et al., 1997). Little is known about the biological mechanisms which 
could account for these differences in clinical behavior. Viro-clinical studies have reported 
that the outcome of cervical cancer was related to the type of HPV associated to the tumour. 
A favourable course was observed for tumours associated with HPV58 and related types (Lai 
et al., 1999) whereas association with HPV18 was found to be indicative of poor outcome 
(Burger et al., 1996; Lombard et al., 1998). 
To get insight into the molecular mechanisms controlling the progression of invasive cervical 
carcinoma, we have designed a gene expression study on cases selected according to viral and 
clinical parameters. HPV16- and HPV18-associated tumours were included in order to 
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determine whether specific gene expression profile could characterize these HPV types. To 
determine whether a characteristic pattern of gene expression could be linked to the disease 
course, we also analysed cases with favourable outcome and tumours which presented an 
early relapse uncontrolled by the treatment. A combination of unsupervised Coupled Two-
Way Clustering (CTWC) (Getz et al., 2000) and Sorting Points Into Neighbourhoods (SPIN) 
(Tsafrir et al., 2005) methods was employed to mine the expression data, together with the use 
of rigourous statistical tests, thus combining the benefits of both knowledge and data driven 
approaches. One major finding of our analysis was the identification of a ‘Cervical Cancer 
Proliferation Cluster’ (CCPC) composed of 163 highly correlated transcripts, many of which 
corresponded to genes controlling cell proliferation. We found that tumours with an early 
relapse had an average expression level of CCPC genes higher than that of tumours with a 
favourable course, suggesting that the CCPC may be indicative of disease outcome. 
Moreover, we showed that E6/E7 mRNA expression was positively correlated with the 
expression level of the CCPC genes and to viral DNA load. Altogether, these findings suggest 
that tumour cell proliferation is dependent on E6/E7 mRNA levels and that HPV DNA load, 
positively correlated to E6/E7 mRNA level, may be associated with the outcome of invasive 
carcinoma of the uterine cervix.  
 
RESULTS 
Global data overview 
Unsupervised analysis separated tumour samples according to their histological type  
Gene expression profiling was performed on 45 samples (5 normal mucosa, 5 cell lines, and 
35 primary tumours including 5 duplicates) with Affymetrix HG-U133A oligonucleotide 
microarray (Table 1). Samples in duplicates exhibited high similarity in expression profiles 
(average correlation of 0.95). In order to generate an overview of the data and to identify 
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major partitions and relationships, we filtered the genes with highest variance and ordered the 
resulting expression matrix in SPIN (Figure 1). Two separate ordering operations were 
performed: one on the genes (rows; Figure 1c) and another on the samples (columns; Figure 
1b). The two-way organized expression matrix (Figure 1d) permitted thus to study 
concurrently the structure of both samples and genes. Unsupervised ordering in the context of 
the most varying transcripts separated the samples in complete agreement with the nature of 
the 3 types of samples: normal mucosa, primary tumours and cell lines. Furthermore, a clear 
distinction was seen within the tumour samples according to their histological type (SCC 
versus AC). All this information is visually displayed in the SPIN permutated distance matrix 
for the samples (Figure 1b). While the PCA image (Figure 1a) provides only the top principal 
directions (here, 3), the distance matrices and the reordered expression matrix contain the full 
high-dimensional relationships (Tsafrir et al., 2005). 
At this stage we did not detect any expression signal associated with differences in viral type 
or disease outcome. 
Supervised analysis 
Supervised hypothesis testing corroborated our observations regarding the grouping of 
samples. Using the t-test with 5% FDR statistical confidence, we found that 2507 of 22,215 
probe sets (11.3%) were differentially expressed in the tumour samples as compared with the 
normal samples, with 1206 probe sets (which include 849 unique annotated genes and 178 
ESTs) showing overexpression in tumour samples (supplementary tables). Among these, the 
major and most significant functional groups were: DNA metabolism (n=96), mitotic cell 
cycle (n=93), regulation of cell cycle (n=59), DNA replication and chromosome cycle (n=56), 
and DNA repair (n=35). Among the known genes which were overexpressed in tumours as 
compared to normal cervix, 94 were also found to be overexpressed in primary tumours when 
compared to the cell lines (supplementary tables). The majority of these genes were involved 
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in immune response and were related to stroma cells. Among the tumour samples, 6.86% of 
the probe sets were differentially expressed in SCC as compared to AC.  
As in unsupervised analysis, no single gene separated the tumour samples according to either 
viral type or disease outcome (using the constraint of 5% FDR significance level). 
A gene cluster associated with disease outcome includes mostly proliferation genes 
In a second step, we focused on one gene cluster, including 163 probe sets, identified by using 
CTWC on the 5000 probe sets with the highest variance. The expression profile of the genes 
of this cluster separated the samples into four groups: a group composed of all normal 
samples, a second group including 7 primary tumours among which 6 presented a favourable 
outcome (‘favourable outcome group’), a third group containing the remaining primary 
tumours, and a fourth group composed of all cell lines (Figure 2). The P value for having only 
6 favourable outcome tumours and 1 unfavourable outcome tumour in one group is 0.06, 
according to one-tail Fisher exact test. It should be stressed that this is not a separation 
according to outcome, since only a subset of tumours with favourable outcome belongs to the 
‘favourable outcome group’. This makes it impossible to identify this group of genes by using 
a supervised test designed according to tumour outcome. Figure 2 shows the expression 
matrix of the corresponding dendrogram: the normal samples had the lowest expression 
levels, the ‘favourable outcome group’ was closest to the normal samples and the cell lines 
had the highest expression levels. 
The 163 probe sets included in this gene cluster correspond to 123 unique genes and 16 ESTs 
(Table 2). Looking at Gene Ontology biological process annotations, we found that 55 of 
these genes were related to cell cycle, 30 to nuclear division, 29 to M-phase of mitotic cell 
cycle, 28 to regulation of cell cycle, and 22 to DNA replication and chromosome cycle. All 
these annotations have p-value < 10-10 according to Fisher Exact test. Consequently, we refer 
to this gene cluster as the ‘Cervical Cancer Proliferation Cluster’ (CCPC). 
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Even though not a single gene separated the patients according to outcome (at FDR of 5%), 
the average expression levels of the CCPC genes was higher in the unfavourable outcome 
tumours when compared to the favourable outcome tumours (P = 0.026, t-test). This 
difference becomes much more significant when the average expression levels of the CCPC 
genes was compared between the 6 ‘favourable outcome tumours’ and all the other tumours 
(P value in the 10-6 range). 
Validation of the ‘Cervical Cancer Proliferation Cluster’ by qRT-PCR 
Quantitative RT-PCR was performed in order to validate the microarray expression 
measurements and to increase the number of samples on which the prognostic value of the 
proliferation cluster is tested.  Twenty genes were selected from the CCPC and analysed using 
qRT-PCR in 70 samples: the 5 cells lines and the 28 of 30 invasive carcinomas with known 
disease outcome previously analysed by Affymetrix array, 30 additional invasive carcinomas 
and 2 additional cell lines (IC4 and IC8) (see supplementary table 1 for tumor characteristics). 
To select these genes, probe sets from the CCPC were sorted according to their ability to 
separate the 6 tumours with favourable outcome from the 13 tumours with unfavourable 
outcome using a T-test, and fold-change ratio between the average expressions of the two 
groups. The 20 genes that showed the best combination of low p-value and high fold-change 
were selected (Table 3). A high Pearson correlation between qRT-PCR gene expression level 
and Affymetrix signal for the corresponding probe set was observed (mean = 0.88, median = 
0.89) (Table 3 and supplementary figure 1). 
Cluster analysis of the samples, using the qRT-PCR results revealed a tumour group that 
contained 9 favourable outcome tumours including the 6 tumours previously identified 
(‘favourable outcome group’), as well as 1 normal sample, and 3 unfavourable outcome 
tumours. The P value for having 9 favourable outcome tumours and 3 unfavourable outcome 
tumours in one group is 0.076 according to one-tail Fisher exact test. These results indicated 
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that some of the genes chosen for the qRT-PCR could be potential markers for cervical cancer 
outcome. 
E6 and E7 expression correlates with the ‘Cervical Cancer Proliferation Cluster’ 
expression level and with viral DNA load 
The viral proteins E6 and E7 bind to and inhibit TP53 and pRB, respectively, driving the cell 
into proliferation (Figure 3). We therefore hypothesized that variation in expression level of 
the CCPC genes might correlate with E6/E7 mRNA levels. E6 and E7 mRNA expression was 
measured by qRT-PCR for HPV16 tumours (n = 35) and HPV18 tumours (n = 18) separately. 
Quantitative RT-PCR showed great variations in E7 expression levels among tumour samples. 
2-∆∆CT expression values ranged from 0.002 to 12.46 (mean 2.75±2.58) in HPV16 tumours and 
from 0.22 to 9.77 (mean 1.54±2.14) in HPV18 tumours. E6 expression was highly correlated 
with E7 expression in HPV16/18 tumours (R = 0.792, p<0.0001, linear regression). We thus 
used only E7 expression for further correlation analysis. 
Considering the large variations in E7 expression among the different samples, we 
hypothesized that the mRNA levels of E7 depended on the number of HPV genomes per 
neoplastic cells. To test this hypothesis, E7 DNA load was also measured by qRT-PCR, for 
HPV16 tumours (n = 34) and HPV18 tumours (n = 17) separetely. We found that E7 mRNA 
expression level was correlated with E7 DNA load (Spearman correlation of 0.47 for HPV16 
tumours, 0.66 for HPV18 tumours). Furthermore, E7 RNA level was highly correlated with 
the expression level of the CCPC genes measured by Affymetrix array and with that of the 20 
selected genes measured by qRT-PCR (Table 4 and Figure 3). We also found a correlation 
between the expression level of the CCPC genes and E7 DNA levels although the correlation 
coefficient was lower than for E7 RNA levels (r = 0.33 for HPV16 tumors and r = 0.55 for 
HPV18 tumors) (Table 4 and Figure 3). 
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To evaluate whether high correlation with E7 mRNA expression was characteristic of the 
CCPC genes, Spearman’s Rho correlation was measured between the mRNA expression 
levels of E7 and the expression levels of all probe sets of the HG-U133A Affymetrix 
microarray (supplementary tables and supplementary figure 2). In HPV16 tumours, 195 probe 
sets were highly positively correlated (R>0.7) to E7 mRNA expression levels while 230 probe 
sets were found correlated in HPV18 tumours. CCPC genes were over-represented among 
these probe sets, both in HPV16 tumours (55/195, 33.7%) and in HPV18 tumours (37/230, 
22.7%). A group of 33 probe sets had a correlation coefficient >0.7 for both HPV16 and 
HPV18 tumours (P < 10-30, hypergeometric test). Gene ontology annotations of these probe 
sets are cell cycle, M-phase, S-phase, regulation of cell cycle, DNA regulation and DNA 
metabolism. From the 20 known genes of these 33 probe sets, 11 (55%) are known targets of 
the RB-E2F pathway (Markey et al., 2002; Muller et al., 2001; Ren et al., 2002). Surprisingly, 
genes negatively correlated to E6/E7 expression levels did not include many known TP53 
targets, such as CDKN1A or GADD45A. 
Correlation between gene expression analysis and disease outcome 
Assigning an outcome indicator value -1 for unfavourable prognosis and +1 for favourable 
prognosis, we measured the Pearson correlation of various quantities with outcome. Pearson 
correlation coefficient between the average expression level of the 163 CCPC probes sets and 
outcome was 0.42 (P = 0.02). Interestingly, this correlation coefficient was higher for the 
HPV18 tumours compared to the HPV16 tumours: R = 0.65 (P = 0.01) versus R = 0.31 (P = 
0.1), respectively. We also calculated Pearson correlation coefficient between disease 
outcome and E7 mRNA expression levels. We obtained a significant correlation only for the 
HPV18 tumours: R = 0.39 (P = 0.01). 
 
DISCUSSION  
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Gene expression profiling in cervical carcinoma specimens using CTWC analysis identified a 
cluster of 163 transcripts, mostly related to cell proliferation (CCPC genes) and differentially 
expressed according to disease outcome. Importantly, expression levels of the CCPC genes 
were found positively correlated to E6/E7 mRNA levels. These results indicate that, in 
agreement with the observations performed by in vitro studies on cell lines, E6 and E7 viral 
oncogenes play a key role in the progression of invasive cervical carcinoma via the 
deregulation of cellular genes controlling cell proliferation. Interestingly, 54 of the 123 CCPC 
genes (44%) correspond to previously reported E2F targets (Table 2) (Markey et al., 2002; 
Muller et al., 2001; Ren et al., 2002). The mechanisms by which E7 interferes with the 
regulation of proliferation, notably the inactivation of the pRB protein and the subsequent 
release of active E2F transcription factor, have been largely documented (Munger et al., 
2004). It is of interest to stress that analyses of gene expression profiles in cancer-derived 
cells have identified clusters of genes under the control of E2F, which are largely common to 
the CCPC genes (Milyavsky et al., In press; Thierry et al., 2004; Wells et al., 2003). E2F is in 
turn controlled directly by RB and indirectly by TP53 (Tabach et al., Submitted). In HPV18-
associated HeLa cells, the switch of E6/E7, through the regulated expression of E2, led 
Thierry et al. to identify a subset of 28 mitotic genes, among which 19 (68%) were common 
to the CCPC genes and 12 corresponded to E2F targets (AURKB, CDC20, CCNA2, CCNB2, 
MAD2L1, MKI67, MYBL2, NEK2, PTTG1, RRM2, TOP2A, UBE2C) (Thierry et al., 2004). 
Large-scale gene expression analyses of cervical neoplasia published so far aimed at 
identifying molecular markers associated with the progression of lesions (Chen et al., 2003; 
Sopov et al., 2004; Wong et al., 2003) but reported no data concerning the expression of the 
viral oncogenes. Chen et al. identified 62 genes overexpressed in high-grade compared to 
low-grade squamous intra-epithelial lesions, four of which were common to the CCPC genes 
(TK1, MYBL2, MCMC4, TOP2A). In our study, the E6 and E7 genes were found to be co-
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expressed in tumour samples and the respective impact of these viral oncoproteins on cell 
proliferation has to be specified. However, almost no primary known TP53 targets were found 
negatively correlated to E6/E7 expression levels among all Affymetrix probe sets. This result 
suggest that the expression level of E7 is the main driver of tumor cell proliferation in cervical 
cancer. In contrast, possibly, a high sensitivity of TP53 to even low levels of E6 may be 
sufficient to inactivate the TP53 pathway.  
Another striking feature of our results was that a wide range of E6/E7 expression levels was 
observed among tumour cases. A putative role for cellular genes on the control of viral 
oncogenes has not been reported in cancer cells and we hypothesized that differences in 
E6/E7 mRNA expression levels could be related, at least in part, to variations in HPV DNA 
copy number between tumours. We found a positive correlation between E6/E7 mRNA levels 
and viral DNA load in tissue specimens. Histological analysis showed that all samples 
contained more than 50% of invasive carcinoma cells and it is unlikely that the correlation 
observed was related to differences in carcinoma cell density or in tumour differentiation. 
The differences in E6/E7 expression levels observed between cases may also be related to 
differences in the physical state of viral DNA. Although integrated sequences are detected in 
most invasive carcinoma (Cullen et al., 1991), a proportion of cases contains only episomal 
HPV DNA (Klaes et al., 1999; Matsukura et al., 1989). A deregulated expression of integrated 
viral DNA (Schneider-Gadicke & Schwarz, 1986) and a high stability of E6/E7 mRNAs 
derived from integrated sequences (Jeon et al., 1995) account for a higher level of E6/E7 
expression derived from integrated viral DNA compared to that from episomal viral DNA. It 
is worth to be mentioned that most of HPV18 sequences associated with cervical cancer are 
found integrated into the host genome (Cullen et al., 1991). A high transcription rate of 
HPV18 oncogenes can thus account for the rapid progression of cervical carcinoma associated 
with this virus type (Lombard et al., 1998; Wang & Lu, 2004). 
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Viro-clinical analyses reported that a high viral load was related to a higher risk of 
progression of low-grade to high-grade intraepithelial neoplasia (Dalstein et al., 2003) and to 
the persistence of high-grade lesions (Ho et al., 1995), but few studies have analysed the 
influence of HPV DNA copy number on the course of invasive cancers. A high HPV DNA 
load has been found positively correlated to tumour differentiation (Ikenberg et al., 1994) and 
negatively correlated to clinical stage (Berumen et al., 1994). However, no link has been 
reported between viral DNA load and cell proliferation or disease outcome. Analysis of a 
large number of cases at different clinical stages is needed to determine whether viral DNA 
load could be used as an independent biological marker of the outcome of invasive carcinoma.  
To further support the correlation with disease outcome, we checked the CCPC on an 
available breast cancer gene expression dataset (van 't Veer et al., 2002). This study was based 
on a different DNA microarray, in which only 49 genes corresponding to the 163 probe sets of 
the CCPC were represented. Among those, we searched for genes that could separate 
unfavourable outcome tumours from favourable outcome tumours. Using t-test, we found that 
the expression levels of 31 genes passed the 5% FDR threshold and were able to separate 
favourable outcome breast tumours from unfavourable outcome tumours (supplementary 
figure 3). These results indicate that the CCPC may be useful to predict outcome in other 
tumour types. 
In summary, CTWC analysis in a series of invasive carcinoma of the uterine cervix identified 
a proliferation gene cluster whose expression was found positively correlated with E6/E7 viral 
oncogenes expression and, to a lower extent, with HPV DNA load. HPV expression level may 
thus correspond to a biological marker of interest in both prognosis assessment and targeted 
therapy design of invasive carcinoma of the uterine cervix. 
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MATERIALS AND METHODS 
Cervical Tissue Samples and Cell Lines 
Primary tumour samples (n=60) from invasive cervical carcinoma were selected from the 
Institut Curie tumour bank. Characteristics are listed in table 1 and supplementary table 1. 
Patient’s age ranged from 23 to 78 year-old (median, 46). HPV status was determined by 
PCR, as described (Rosty et al., 2004). Relapse-free survival (RFS) was defined as the 
interval elapsed between the date of the first symptoms and that of local recurrence and/or 
distant metastasis. Cases with RFS >5 years (n=30) were classified as diseases with 
favourable outcome and those with RFS <3 years (n=27) as diseases with unfavourable 
outcome. 
All tumour samples had been flash-frozen and stored at -80°C. Histological analysis of 
tumour tissues adjacent to the selected samples showed that tumour samples contained >50% 
of invasive carcinoma cells. 
Normal exocervical mucosa has been sampled and flash-frozen from 5 hysterectomy 
specimens, removed for non-cervical diseases. Cell lines (IC1, IC3 to 8) were established 
from human primary invasive cervical carcinoma (Couturier et al., 1991; Sastre-Garau et al., 
2000). Samples from the primary tumours corresponding to IC5, IC6, and IC8 were included 
in this series (#25, #16, and #31, respectively). 
Labeling and Microarray Hybridization 
A total of 45 cervical samples were analysed: 30 taken from invasive carcinoma with 5 
duplicates, 5 from normal mucosa, and 5 corresponding to carcinoma-derived cell lines (IC1, 
IC3, IC5 to 7) (Table 1). Total RNAs were extracted from each sample by caesium chloride 
ultracentrifugation. RNA quality was assessed by visualization of the 28S/18S ribosomal 
RNA ratio on electrophoresis gel. Complementary RNA target was prepared and labelled as 
described in the Affymetrix GeneChip Expression Analysis Technical Manual (High 
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Wycombe, United Kingdom). The labelled target was hybridized to Affymetrix HG-U133A 
oligonucleotide microarray, representing 22 215 probe sets. To control the reproducibility of 
the results, hybridization was performed in duplicate for 5 tumour samples.  
Quantitative Real-Time PCR 
Reverse transcription was performed using 1 µg of total RNA, random hexamer primer, and 
the SuperScript II reverse transcription kit (Invitrogen, Cergy Pontoise, France). Real-time 
PCR was performed in the SYBR Green format (Applied Biosystems, Courtaboeuf, France) 
for STK6, H2AFZ, KPNA2, CDC20 and to amplify E6 and E7 HPV transcripts for HPV16 
tumours and HPV18 tumours. For normalization, TBP expression was used. Primer sequences 
were GTC AGT ACA TGC TCC ATC TTC (forward) and GTG AAT TCA ACC CGT GAT 
ATT C (reverse) for STK6; CTC ACC GCA GAG GTA CTT G (forward) and TTG TCC 
TTT CTT CCC AAT CAG (reverse) for H2AFZ ; TCA AGC TGC CAG GAA ACT ACT 
(forward) and GCC TTG GTT TGT TCT GAT GTC (reverse) for KPNA2; CTG TCC AGT 
GGT TCA CGT TC (forward) and CCT TGA CAG CCC CTT GAT G (reverse) for CDC20 ; 
GAG CGA CCC AGA AAG TTA CCA (forward) and AAA TCC CGA AAA GCA AAG 
TCA (reverse) for E6 HPV16; TCC AGC TGG ACA AGC AGA AC (forward) and CAC 
AAC CGA AGC GTA GAG TC (reverse) for E7 HPV16; AAT AAG GTG CCT GCG GTG 
(forward) and CTT GTG TTT CTC TGC GTC GT (reverse) for E7 HPV16; AAC ATT TAC 
CAG CCC GAC GA (forward) and TCG TCT GCT GAG CTT TCT AC (reverse) for E7 
HPV18; AGT GAA GAA CAG TCC AGA CTG (forward) and CCA GGA AAT AAC TCT 
GGC TCA T (reverse) for TBP.  
The Applied Biosystems Assays-on-Demand™ Gene Expression system (Applied 
Biosystems, Courtaboeuf, France) was used to analyse gene expression of 16 human genes: 
ANKT, GGH, CCNB2, BUB1B, FEN1, CCNB1, OIP5, MELK, MCM4, UBE2C, PLK, 
CDC2, ZWINT, CCNA2, TOPK, RRM2. All samples were tested in duplicate. Analysis was 
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performed using SDS v2.1 software (Applied Biosystems) according to the manufacturer’s 
instructions. For each mRNA sample, a difference in CT values (∆CT) was calculated by 
taking the mean CT of duplicate reaction and subtracting the mean CT of the duplicate reaction 
of the reference (TBP) RNA. A normal cervical sample was used as the calibrator. The 2-∆∆CT 
method was used for quantification of gene expression (Livak & Schmittgen, 2001). 
HPV viral load was quantified on tumour DNA using E7 primers specific for HPV16 and 
HPV18, in 34 HPV16 tumours and in 17 HPV18 tumours (same primer sets as for RNA 
expression analysis). We chose PSA as the reference gene. Primers for PSA were AGG CTG 
GGG CAG CAT TGA AC (forward) and CAC CTT CTG AGG GTG AAC TTG (reverse). 
Comparative genomic hybridization analysis of the same tumour samples (manuscript in 
preparation) showed that the chomosomal location where PSA maps (19q13) has little if any 
variation in DNA copy number. 
Data Analysis 
Data Preprocessing. The Microarray Suite 5.0 software (MAS v5.0, Affymetrix) was used to 
scale the raw data and produce an expression matrix, where each value was the expression 
level of one transcript measured in one sample. In order to avoid working with unreliably 
small numbers, gene expression values below 10 were set to 10 and a log2 transformation was 
applied (Tsafrir et al., 2005). When the Affymetrix data was used to measure correlation with 
E7 PCR measurements, log2 transformation and thresholding were not applied. 
Genes were chosen for unsupervised analysis on the basis of their standard deviations. For 
duplicated tumour samples, the assigned value was the average of the two duplicates (except 
for the unsupervised analysis in the global overview, where both duplicates were represented). 
Unsupervised analysis: Since hypothesis testing can not reveal unexpected partitions, 
unsupervised techniques, such as clustering, are more suited for such a task. The CTWC 
method (Getz et al., 2000) focuses on correlated subsets of genes and samples, such that when 
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one is used to cluster the other, stable and significant partitions emerge. The underlying 
algorithm is based on iterative clustering, enabling identification of biologically relevant 
subsets of the data. This reveals partitions and correlations that are masked when the full 
dataset is used in the analysis. For example, when a particular set of genes is used to cluster 
the samples we find that they divide into 2 groups: a relatively tight cluster of predominantly 
favourable outcome tumours, and a larger cluster containing both favourable and 
unfavourable outcome tumours. The statistical significance of this ‘favourable outcome 
group’ was measured with Fisher exact test (Fisher, 1935). 
Another exploratory analysis method that uses groups of correlated genes for meaningful 
ordering of tumours is SPIN (Tsafrir et al., 2005), our recently proposed methodology for data 
organization and visualization. At the heart of this method is a presentation of the full 
pairwise distance matrix of the samples, viewed in pseudo-color. The samples are iteratively 
permuted in search of an optimal ordering, i.e. one that can be used to study embedded 
shapes. Hence, certain structures in the data (elongated, circular and compact) manifest 
themselves visually in a SPIN generated distance matrix. 
Supervised analysis. Supervised methods were employed in order to expand and refine the list 
of genes that was obtained by the unsupervised step. In order to control contamination with 
false positive genes associated with multiple comparisons, we used the method of Benjamini 
and Hochberg (Benjamini & Hochberg, 1995) that defines the average false discovery rate 
(FDR); namely, the fraction of false positives among the list of differentiating genes.  
qRT-PCR analysis 
The data analysis of the qRT-PCR for the selected genes was based on samples previously 
analysed with Affymetrix array with 30 additional primary tumours and 2 additional cell 
lines. Missing values were completed using a K-nearest neighbours algorithm (Troyanskaya 
et al., 2001). 
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E7 analysis 
The samples used for this qRT-PCR analysis were 35 HPV16 tumours (including 2 cell lines), 
16 of which were used previously for the Affymetrix arrays, and 18 HPV18 tumours 
(including 4 cell lines), of which 14 were used for the Affymetrix arrays. Normal samples 
were added with assigned values of 0 for E7 mRNA and DNA expression. Correlations of E7 
expression with other genes were calculated using Spearman’s Rho correlation.  
Gene Ontology Annotation 
For Gene Ontology (GO) annotation we used the web site 
http://apps1.niaid.nih.gov/David/upload.asp (Dennis et al., 2003) that produces p-values 
according to Fisher exact test for the statistical significance of the measured over (or under) 
representation of a specific functional annotation, among members of a particular group of 
probe sets. Another web site used for GO annotation is the Affymetrix Analysis Center 
http://www.affymetrix.com/analysis/netaffx/index.affx (Liu et al., 2003). 
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TABLES 
Table 1. Clinical and pathological characteristics of the 40 cervical tissue specimens analysed 
by Affymetrix HG-U133A oligonucleotide microarray. The characteristics of all specimens 
used are listed in supplementary table 1. 
HPV type Outcome 
Tissue specimens 
HPV16 HPV18 Others Favourable Unfavourable NA 
Primary Tumors 
16 12 2 15 13 2 
        SCC (n=20) 12 6 2 9 10 1 
        AC (n=10) 4 6 0 6 3 1 
Cell lines (n=5) 2 3 0 - - - 
Normal cervix (n=5) - - - - - - 
SCC: Squamous Cell Carcinoma; AC: Adenocarcinome; NA: Non Available. 
 
Table 2. List of the 123 unique known genes corresponding to the 163 transcripts of the 
“Cervical Cancer Proliferation Cluster”, identified by coupled two-way clustering analysis. 
Genes previously reported as E2F targets are underlined. 
 
Probe Set ID  Gene Symbol  Gene Title 
212186_at ACACA acetyl-Coenzyme A carboxylase alpha 
218039_at ANKT nucleolar protein ANKT 
208103_s_at ANP32E acidic nuclear phosphoprotein 32 family, member E 
206632_s_at APOBEC3B apolipoprotein B mRNA editing enzyme, catalytic polypeptide-like 3B 
218115_at ASF1B ASF1 anti-silencing function 1 homolog B 
204244_s_at ASK activator of S phase kinase 
219918_s_at ASPM asp (abnormal spindle)-like, microcephaly associated 
209464_at AURKB aurora kinase B 
202094_at BIRC5 baculoviral IAP repeat-containing 5 (survivin) 
204531_s_at BRCA1 breast cancer 1, early onset 
212949_at BRRN1 barren homolog 
209642_at BUB1 BUB1 budding uninhibited by benzimidazoles 1 homolog 
203755_at BUB1B BUB1 budding uninhibited by benzimidazoles 1 homolog beta 
209301_at CA2 carbonic anhydrase II 
203418_at CCNA2 cyclin A2 
214710_s_at CCNB1 cyclin B1 
202705_at CCNB2 cyclin B2 
205034_at CCNE2 cyclin E2 
204826_at CCNF cyclin F 
203213_at CDC2 cell division cycle 2, G1 to S and G2 to M 
202870_s_at CDC20 CDC20 cell division cycle 20 homolog 
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203967_at CDC6 CDC6 cell division cycle 6 homolog 
221436_s_at CDCA3 cell division cycle associated 3 
221520_s_at CDCA8 cell division cycle associated 8 
207039_at CDKN2A cyclin-dependent kinase inhibitor 2A 
205165_at CELSR3 cadherin, EGF LAG seven-pass G-type receptor 3 
204962_s_at CENPA centromere protein A, 17kDa 
205046_at CENPE centromere protein E, 312kDa 
207828_s_at CENPF centromere protein F, 350/400ka 
204775_at CHAF1B chromatin assembly factor 1, subunit B 
205394_at CHEK1 CHK1 checkpoint homolog 
204170_s_at CKS2 CDC28 protein kinase regulatory subunit 2 
202532_s_at DHFR dihydrofolate reductase 
203764_at DLG7 discs, large homolog 7 
213647_at DNA2L DNA2 DNA replication helicase 2-like 
220668_s_at DNMT3B DNA (cytosine-5-)-methyltransferase 3 beta 
218567_x_at DPP3 dipeptidylpeptidase 3 
217901_at DSG2 desmoglein 2 
203270_at DTYMK deoxythymidylate kinase 
202779_s_at E2-EPF ubiquitin carrier protein 
204947_at E2F1 E2F transcription factor 1 
202735_at EBP emopamil binding protein 
219787_s_at ECT2 epithelial cell transforming sequence 2 oncogene 
221539_at EIF4EBP1 eukaryotic translation initiation factor 4E binding protein 1 
204817_at ESPL1 extra spindle poles like 1 
203358_s_at EZH2 enhancer of zeste homolog 2 
218875_s_at FBXO5 F-box only protein 5 
204767_s_at FEN1 flap structure-specific endonuclease 1 
202580_x_at FOXM1 forkhead box M1 
203560_at GGH gamma-glutamyl hydrolase 
218350_s_at GMNN geminin, DNA replication inhibitor 
204318_s_at GTSE1 G-2 and S-phase expressed 1 
205436_s_at H2AFX H2A histone family, member X 
200853_at H2AFZ H2A histone family, member Z 
218663_at HCAP-G chromosome condensation protein G 
204162_at HEC highly expressed in cancer, rich in leucine heptad repeats 
220085_at HELLS helicase, lymphoid-specific 
206074_s_at HMGA1 high mobility group AT-hook 1 
208808_s_at HMGB2 high-mobility group box 2 
207165_at HMMR hyaluronan-mediated motility receptor 
217755_at HN1 hematological and neurological expressed 1 
204444_at KIF11 kinesin family member 11 
206364_at KIF14 kinesin family member 14 
218755_at KIF20A kinesin family member 20A 
204709_s_at KIF23 kinesin family member 23 
209408_at KIF2C kinesin family member 2C 
218355_at KIF4A kinesin family member 4A 
209680_s_at KIFC1 kinesin family member C1 
219306_at KNSL7 kinesin-like 7 
201088_at KPNA2 karyopherin alpha 2 
203276_at LMNB1 lamin B1 
208433_s_at LRP8 low density lipoprotein receptor-related protein 8 
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202736_s_at LSM4 LSM4 homolog, U6 small nuclear RNA associated 
203362_s_at MAD2L1 MAD2 mitotic arrest deficient-like 1 
210059_s_at MAPK13 mitogen-activated protein kinase 13 
220651_s_at MCM10 MCM10 minichromosome maintenance deficient 10 
202107_s_at MCM2 MCM2 minichromosome maintenance deficient 2 
212141_at MCM4 MCM4 minichromosome maintenance deficient 4 
204825_at MELK maternal embryonic leucine zipper kinase 
212020_s_at MKI67 antigen identified by monoclonal antibody Ki-67 
205235_s_at MPHOSPH1 M-phase phosphoprotein 1 
221437_s_at MRPS15 mitochondrial ribosomal protein S15 
201710_at MYBL2 v-myb myeloblastosis viral oncogene homolog (avian)-like 2 
204641_at NEK2 NIMA (never in mitosis gene a)-related kinase 2 
218888_s_at NETO2 neuropilin (NRP) and tolloid (TLL)-like 2 
213599_at OIP5 Opa-interacting protein 5 
203228_at PAFAH1B3 platelet-activating factor acetylhydrolase, isoform Ib 
201202_at PCNA proliferating cell nuclear antigen 
204146_at PIR51 RAD51-interacting protein 
212858_at PKMYT1 protein kinase, membrane associated tyrosine/threonine 1 
218644_at PLEK2 pleckstrin 2 
202240_at PLK polo-like kinase 
213226_at PMSCL1 polymyositis/scleroderma autoantigen 1, 75kDa 
204441_s_at POLA2 polymerase (DNA-directed), alpha (70kD) 
213007_at POLG polymerase (DNA directed), gamma 
207746_at POLQ polymerase (DNA directed), theta 
218009_s_at PRC1 protein regulator of cytokinesis 1 
218782_s_at PRO2000 PRO2000 protein 
203554_x_at PTTG1 pituitary tumor-transforming 1 
222077_s_at RACGAP1 Rac GTPase activating protein 1 
218585_s_at RAMP RA-regulated nuclear matrix-associated protein 
209507_at RPA3 replication protein A3, 14kDa 
201890_at RRM2 ribonucleotide reductase M2 polypeptide 
219493_at SHCBP1 likely ortholog of mouse Shc SH2-domain binding protein 1 
205339_at SIL TAL1 (SCL) interrupting locus 
218653_at SLC25A15 solute carrier family 25 member 15 
218237_s_at SLC38A1 solute carrier family 38, member 1 
213253_at SMC2L1 SMC2 structural maintenance of chromosomes 2-like 1 
201663_s_at SMC4L1 SMC4 structural maintenance of chromosomes 4-like 1 
203145_at SPAG5 sperm associated antigen 5 
204092_s_at STK6 serine/threonine kinase 6 
218308_at TACC3 transforming, acidic coiled-coil containing protein 3 
202338_at TK1 thymidine kinase 1, soluble 
203432_at TMPO thymopoietin 
217733_s_at TMSB10 thymosin, beta 10 
201291_s_at TOP2A topoisomerase (DNA) II alpha 170kDa 
219148_at TOPK T-LAK cell-originated protein kinase 
210052_s_at TPX2 TPX2, microtubule-associated protein homolog 
204033_at TRIP13 thyroid hormone receptor interactor 13 
204822_at TTK TTK protein kinase 
202589_at TYMS thymidylate synthetase 
202954_at UBE2C ubiquitin-conjugating enzyme E2C 
204026_s_at ZWINT ZW10 interactor 
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Table 3. Selection of genes from the proliferation cluster genes for qRT-PCR analysis. The 
third column contains P values of the T-test used for comparison of expression levels between 
the ‘favourable outcome tumour group’ and the 13 unfavourable outcome tumours. The fourth 
column presents the fold change ratio between the average expression of the two tumour 
groups, and the last column shows the Pearson correlation coefficient between expression 
levels measured by Affymetrix array and qRT-PCR. These probe sets were selected out of 84 
probe sets that passed the T-test at 5% FDR. 
 
Probe Set ID 
Gene 
Symbol P-value 
Fold-
change 
Pearson 
correlation  
208079_s_at STK6 4.99.10-7 2.83 0.93 
218039_at ANKT 6.35.10-6 2.06 0.96 
203560_at GGH 5.18.10-6 2.27 0.91 
212141_at MCM4 7.01.10-6 2.51 0.82 
202705_at CCNB2 7.03.10-6 2.54 0.90 
204767_s_at FEN1 8.81.10-6 1.64 0.89 
200853_at H2AFZ 1.66.10-5 2.11 0.77 
204825_at MELK 2.50.10-5 2.40 0.91 
214710_s_at CCNB1 2.88.10-5 2.91 0.93 
209773_s_at RRM2 2.95.10-5 2.63 0.94 
202954_at UBE2C 3.39.10-5 2.07 0.80 
202240_at PLK 6.61.10-5 2.14 0.89 
202870_s_at CDC20 1.61.10-4 2.69 0.94 
211762_s_at KPNA2 1.79.10-4 1.96 0.93 
203418_at CCNA2 2.19.10-4 2.40 0.88 
219148_at TOPK 3.25.10-4 2.55 0.89 
203213_at CDC2 3.42.10-4 2.14 0.88 
204026_s_at ZWINT 4.36.10-4 2.03 0.89 
213599_at OIP5 1.37.10-3 2.93 0.62 
203755_at BUB1B 1.61.10-3 1.56 0.94 
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Table 4. Summary of the Spearman’s Rho average correlation between E7 mRNA 
expression, E7 DNA load and the ‘Cervical Cancer Proliferation Cluster’, for both the 
Affymetrix data and qRT-PCR data. To perform the correlation calculation, normal samples 
were included (E7 expression was set to 0).  
 
Method Tumours Mean correlation
with E7 mRNA 
Mean correlation 
with E7 DNA 
qRT-PCR HPV16 tumours 0.55 0.33 
 HPV18 tumours 0.67 0.55 
Affymetrix HPV16 tumours 0.63 0.54 
 HPV18 tumours 0.68 0.56 
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FIGURE LEGENDS 
Figure 1. Global data overview. The data presented in this figure includes the 1,000 genes 
with highest variance over the 45 samples. Focusing on the most relevant genes by means of 
variance filtration facilited the computations and still gave a good overall picture of the layout 
of the data. (a) Projection of the samples onto the first (x-axis), second (y-axis) and third (z-
axis) principal components (PC), calculated in gene-space. The nature of samples is indicated 
by color: normal cervical mucosa (black); carcinoma cell lines (green); primary squamous cell 
carcinoma (SCC, yellow) and adenocarcinoma (AC, magenta).  The first PC is dominated by 
the differences between the cell lines and all other samples. The second PC is dominated by 
the differences between SCC and AC tumours. The third PC is dominated by the differences 
between normal samples and tumours. (b) SPIN-ordered distance matrix for the samples. 
Colors in the distance matrix depict dissimilarity levels between points, with red (blue) 
indicating large (small) distances. Hence, clusters of highly similar samples are manifested as 
bluish squares around the main diagonal. Note that the cell lines are a distinct, homogeneous 
group (marked by green in the colored bar on the right), while the normal cervical samples are 
clearly separated but are rather heterogeneous. (c) SPIN-ordered distance matrix for the 
genes. Note the grouping into several distinctive profiles. (d) Two-way SPIN-ordered 
expression matrix. Here colors depict relative expression intensities after centering and 
normalization of genes (rows), where red (blue) denotes relatively high (low) expression. 
Rows represent genes and columns represent samples. The colored bar below the matrix 
provides the tissues clinical identity. 
Figure 2. Pattern of expression of the ‘Cervical Cancer Proliferation Cluster’(CCPC). (a) The 
dendrogram above the matrix represents the clusters of the samples identified by CTWC. (b) 
In the expression matrix the samples were ordered according to the dendrogram (generated by 
clustering), whereas the genes were ordered by SPIN. The samples inclued: 5 normals, 5 cell 
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lines, 15 favourable outcome tumours, 13 unfavourable outcome tumours, 2 unknown 
outcome tumours. The color bar below the matrix displays the different origin of samples: 
primary tumours with unfavourable outcome (blue), favourable outcome (red), unknown 
outcome (cyan); cell-line (green), normal samples (black). (c)  Plot of the average expression 
levels of the CCPC genes; the error bars indicate one standard deviation. (d) PCA diagram. 
Data is after log, centering and normalization. The six tumours closest to the normal samples 
are all with favourable outcome. 
Figure 3. Correlations of qRT-PCR genes with E7 mRNA expression and E7 DNA load. (a) 
Schematic drawing of the network that controls expression of the CCPC genes, indicating the 
manner in which the viral proteins E6 and E7 affect the network. (b) For each gene (including 
E7 mRNA and DNA) the measured qRT-PCR values were ranked, separately for HPV16 and 
HPV18 tumours. The resulting "rank matrix" was used to sort the samples; it is presented on 
the left for HPV16 tumours and on the right for HPV18 tumours. Rows represent genes and 
columns represent samples; the entry in row g and column s represents the color code for the 
rank of the expression level of gene g in sample s; blue entries denote low rank and red high 
rank. For the sake of clarity, the ranks of the samples according to E7 mRNA and DNA 
measurements are also represented in the two graphs at the top and bottom. The color bar at 
the very bottom displays the different labels for samples, using the same color scheme as in 
figure 2. Spearman’s Rho mean correlation with E7 mRNA and DNA levels, as described in 
table 4, is presented separately for HPV16 tumours and HPV18 tumours. 
 
 
 
 
 
 
 



